Chowbay Balram, Sharma Amarnath, Zhou Qing-Yu, Cheung Yin Bun, Lee Edmund J D
Clinical Pharmacology Unit, Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre, Singapore 11, Hospital Drive, Singapore 169610, Singapore.
Oncol Rep. 2003 May-Jun;10(3):745-51.
Diarrhoea is the major dose-limiting toxicity of irinotecan hydrochloride (CPT-11) in the clinical setting. This study was designed to evaluate the effects of different pharmacological agents in the modulation of CPT-11 induced diarrhoea in Sprague-Dawley rats. We studied the effects of intravenous valproic acid (VPA), ceftriaxone (CTX) and oral charcoal in the modulation of CPT-11 induced diarrhoea. Male Sprague-Dawley rats (n=7 per group) were given CPT-11 60 mg/kg as intravenous injection from day 1 to 5 (total dose 300 mg/kg) in all treatment groups. Group 1 (G1) rats only received CPT-11, group 2 to 6 (G2 to G6) rats received in addition to IV CPT-11 60 mg/kg, IV valproic acid (VPA) 200 mg/kg (G2), IV VPA 200 mg/kg + IV ceftriaxone (CTX) 100 mg/kg (G3), IV VPA 200 mg/kg + oral activated charcoal 250 mg administered twice daily (G4), IV CTX 100 mg/kg (G5) and oral charcoal 250 mg every 12 hourly (G6). We compared the pharmacokinetics of total CPT-11 and its metabolites and the frequency and grade of diarrhoea in each group of rats. There were no significant differences in the pharmacokinetic parameters of total CPT-11 between treatment groups (p>0.05). Cotreatment with CTX and charcoal resulted in a lower total SN-38G AUC0- infinity (p<0.05 and p<0.01, respectively). Cotreatment with CTX also resulted in a lower Cmax for total SN-38G compared to other groups (p<0.01). A higher frequency of grade 3 diarrhoea was observed in G1 rats compared to other groups. Co-treatment with VPA (log OR: -1.13; 95% CI: -1.85, -0.41) or CTX (log OR: -1.66; 95% CI: -2.43, -0.88) were found to be associated with a lower odds of grade 3 diarrhoea compared to control or charcoal treated groups. Our findings indicate that CPT-11 treated rats given VPA and CTX, either alone or in combination has similar effects in preventing high grade diarrhoea. Activated charcoal was not found to be effective in the prevention of high grade diarrhoea.
腹泻是盐酸伊立替康(CPT - 11)在临床应用中的主要剂量限制性毒性。本研究旨在评估不同药物制剂对CPT - 11诱导的Sprague - Dawley大鼠腹泻的调节作用。我们研究了静脉注射丙戊酸(VPA)、头孢曲松(CTX)以及口服活性炭对CPT - 11诱导腹泻的调节作用。在所有治疗组中,从第1天到第5天,给雄性Sprague - Dawley大鼠(每组n = 7)静脉注射60 mg/kg的CPT - 11(总剂量300 mg/kg)。第1组(G1)大鼠仅接受CPT - 11,第2至6组(G2至G6)大鼠除静脉注射60 mg/kg的CPT - 11外,还分别接受静脉注射200 mg/kg的丙戊酸(VPA)(G2组)、静脉注射200 mg/kg的VPA + 静脉注射100 mg/kg的头孢曲松(CTX)(G3组)、静脉注射200 mg/kg的VPA + 每日两次口服250 mg活性炭(G4组)、静脉注射100 mg/kg的CTX(G5组)以及每12小时口服250 mg活性炭(G6组)。我们比较了每组大鼠中总CPT - 11及其代谢产物的药代动力学以及腹泻的频率和分级。各治疗组之间总CPT - 11的药代动力学参数无显著差异(p>0.05)。与CTX和活性炭联合治疗导致总SN - 38G的AUC0 - ∞较低(分别为p<0.05和p<0.01)。与其他组相比,CTX联合治疗还导致总SN - 38G的Cmax较低(p<0.01)。与其他组相比,G1组大鼠中3级腹泻的频率更高。与对照组或活性炭治疗组相比,发现与VPA联合治疗(对数比值比:-1.13;95%置信区间:-1.85,-0.41)或CTX联合治疗(对数比值比:-1.66;95%置信区间:-2.43,-0.88)与3级腹泻的较低几率相关。我们的研究结果表明,单独或联合给予VPA和CTX的CPT - 11治疗大鼠在预防重度腹泻方面具有相似的效果。未发现活性炭对预防重度腹泻有效。